‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node mi...

Por Rotman, J., Mom, C. H., Jordanova, E. S., de Gruijl, T. D., Kenter, G. G.
Publicado no BMC Cancer (2018)

HLA-G Expression Is an Independent Predictor for Improved Survival in High Grade Ovarian Carcinomas

Por Rutten, M. J., Dijk, F., Savci-Heijink, C. D., Buist, M. R., Kenter, G. G., van de Vijver, M. J., Jordanova, E. S.
Publicado em 2014

CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients

Por Schrevel, M, Karim, R, ter Haar, N T, van der Burg, S H, Trimbos, J B M Z, Fleuren, G J, Gorter, A, Jordanova, E S
Publicado em 2012

Alternatively spliced tissue factor induces angiogenesis through integrin ligation

Por van den Berg, Y. W., van den Hengel, L. G., Myers, H. R., Ayachi, O., Jordanova, E., Ruf, W., Spek, C. A., Reitsma, P. H., Bogdanov, V. Y., Versteeg, H. H.
Publicado em 2009